Kommende arrangementer

Prescription Drugs and Periodontal Problems
Sted: Gentofte Hotel
Dato: 19. november 2019
Tid: 17:00 - 20:00

Bone Augmentation - Focus on Sinus Lift
Sted: Institute for Anatomy Medical University of Vienna
Dato: 13. marts 2020
Tid: 9:00 - 16:30

Dansk Selskab til Studiet af Parodontologi blev stiftet 23. januar 1953, som den første parodontologiske forening i Danmark.


Formålet med foreningen er at styrke kendskabet til sygdomsudvikling og behandling af marginal parodontitis samt peri-implantitis.
Foreningen har tandlæger som medlemmer og tandplejere som associerede medlemmer, hovedsageligt fra Danmark. Foreningen har i dag små 200 aktive medlemmer.

Foreningen afholder årligt 4 foredrag samt en generalforsamling. Inden hvert foredrag er der en sammenkomst med et lille traktement. Ved generalforsamling, som afholdes i marts/april, er der en middag.

DSP medlemmer har nu mulighed for at deltage i Dansk Parodontologisk Selskab (DPS) møder

Bestyrelsen har fornøjelsen af at informere foreningens medlemmer om, at det nu i kraft af et øget samarbejde mellem de to danske parodontologiske selskaber er muligt, som medlem af Dansk Selskab for Parodontologi at tilmelde sig Dansk Parodontologisk Selskabs forårsmåde til medlemspris. Emnet er endo-parodontale læsioner med professor Henrik Dommisch fra Charité Universitätsmedizin, Berlin. Mødet afholdes både i København og i Aarhus hhv. den 8. og 9. marts..

Tilmelding skal ske via Dansk Parodontologisk Selskabs kasserer Uwe V. Henriksen på kasserer@periodont.dk.

Med venlig hilsen,

Bestyrelsen i DSP

Læs mere

Nyt studie om effekten af parodontalbehandling på blodsukkerniveau hos patienter med type 2 diabetes

Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial.

D’Aiuto F1Gkranias N2Bhowruth D3Khan T3Orlandi M4Suvan J4Masi S3Tsakos G5Hurel S6Hingorani AD3Donos N2Deanfield JE3TASTE Group.

BACKGROUND:

Chronic inflammation is believed to be a major mechanism underlying the pathophysiology of type 2 diabetes. Periodontitisis a cause of systemic inflammation. We aimed to assess the effects of periodontal treatment on glycaemic control in people with type 2 diabetes.

METHODS:

In this 12 month, single-centre, parallel-group, investigator-masked, randomised trial, we recruited patients with type 2 diabetes, moderate-to-severe periodontitis, and at least 15 teeth from four local hospitals and 15 medical or dental practices in the UK. We randomly assigned patients (1:1) using a computer-generated table to receive intensive periodontal treatment (IPT; whole mouth subgingival scaling, surgical periodontal therapy [if the participants showed good oral hygiene practice; otherwise dental cleaning again], and supportive periodontal therapy every 3 months until completion of the study) or control periodontal treatment (CPT; supra-gingival scaling and polishing at the same timepoints as in the IPT group). Treatment allocation included a process of minimisation in terms of diabetes onset, smoking status, sex, and periodontitis severity. Allocation to treatment was concealed in an opaque envelope and revealed to the clinician on the day of first treatment. With the exception of dental staff who performed the treatment and clinical examinations, all study investigators were masked to group allocation. The primary outcome was between-group difference in HbA1c at 12 months in the intention-to-treat population. This study is registered with the ISRCTN registry, number ISRCTN83229304.

FINDINGS:

Between Oct 1, 2008, and Oct 31, 2012, we randomly assigned 264 patients to IPT (n=133) or CPT (n=131), all of whom were included in the intention-to-treat population. At baseline, mean HbA1c was 8·1% (SD 1·7) in both groups. After 12 months, unadjusted mean HbA1c was 8·3% (SE 0·2) in the CPT group and 7·8% (0·2) in the IPT group; with adjustment for baseline HbA1c, age, sex, ethnicity, smoking status, duration of diabetes, and BMI, HbA1c was 0·6% (95% CI 0·3-0·9; p<0·0001) lower in the IPT group than in the CPT group. At least one adverse event was reported in 30 (23%) of 133 patients in the IPT group and 23 (18%) of 131 patients in the CPT group. Serious adverse events were reported in 11 (8%) patients in the IPT group, including one (1%) death, and 11 (8%) patients in the CPT group, including three (2%) deaths.

INTERPRETATION:

Compared with CPT, IPT reduced HbA1c in patients with type 2 diabetes and moderate-to-severe periodontitis after 12 months. These results suggest that routine oral health assessment and treatment of periodontitis could be important for effective management of type 2 diabetes.

Kilde: Pubmed.com

Link til studiet: https://www.ncbi.nlm.nih.gov/pubmed/30472992

Læs mere